Rates of Reproductive Counseling and Contraception Use in Patients with Heart Failure at a Tertiary Care Center
Increasing numbers of women of childbearing age have cardiac disease including heart failure. In these women, pregnancy can cause significant morbidity and mortality. Contraceptive use and pregnancy counseling in women with heart failure is an essential part of their medical care. Here, we assess contraceptive use and pregnancy counseling of patients with heart failure at a single tertiary care center. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 19, 2024 Category: Cardiology Authors: Kristen E. Wong, Amanda K. Verma Source Type: research
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
Treatment of hypertrophic cardiomyopathy (HCM) is generally focused on improving heart failure (HF) symptoms in patients with obstructive HCM (oHCM), with repurposed medicines, invasive septal reduction and, more recently, targeted drug therapy with cardiac myosin inhibitors.1 –4 However, among the one-third of patients with HCM who do not have left ventricular outflow tract (LVOT) obstruction, a substantial proportion develop symptoms that impact daily life and, in some cases, progress to end-stage HF requiring heart transplantation. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 14, 2024 Category: Cardiology Authors: AHMAD MASRI, MARK V. SHERRID, THEODORE P. ABRAHAM, LUBNA CHOUDHURY, PABLO GARCIA-PAVIA, CHRISTOPHER M. KRAMER, ROBERTO BARRIALES-VILLA, ANJALI T. OWENS, FLORIAN RADER, SHERIF F. NAGUEH, IACOPO OLIVOTTO, SARA SABERI, ALBREE TOWER-RADER, TIMOTHY C. WONG, CA Source Type: research
Efficacy and Safety of aficamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
Treatment of hypertrophic cardiomyopathy (HCM) is generally focused on improving heart failure (HF) symptoms in patients with obstructive HCM (oHCM), with repurposed medicines, invasive septal reduction, and more recently targeted drug therapy with cardiac myosin inhibitors.1-4 However, among the one-third of patients with HCM who do not have left ventricular outflow tract (LVOT) obstruction, a substantial proportion develop symptoms that impact daily life and, in some cases, progress to end-stage HF requiring heart transplant. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 14, 2024 Category: Cardiology Authors: Ahmad Masri, Mark V. Sherrid, Theodore P. Abraham, Lubna Choudhury, Pablo Garcia-Pavia, Christopher M. Kramer, Roberto Barriales-Villa, Anjali T. Owens, Florian Rader, Sherif F. Nagueh, Iacopo Olivotto, Sara Saberi, Albree Tower-Rader, Timothy C. Wong, Ca Source Type: research
The Pandemic That Never Left
The COVID-19 pandemic which began in early 2020 had notable effects on public health in the United States (US). The pandemic resulted in direct morbidity and mortality from the effects of COVID-19 but also led to significant disruptions to socioeconomic infrastructure in the US in an effort to contain the pandemic. Although COVID-19 was the third leading cause of mortality in 2021, mortality attributed to COVID-19 remained behind cardiovascular disease and malignancy as the two leading causes of death throughout the early years of the pandemic. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 14, 2024 Category: Cardiology Authors: Abdul Mannan Khan Minhas, Marat Fudim, Dmitry Abramov Tags: JCF Ignite! Source Type: research
Racial Differences in Palliative Care Use in Heart Failure Decedents
Minoritized individuals experience greater heart failure (HF) incidence and mortality, yet racial disparities in palliative care (PC) in HF are unknown. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 14, 2024 Category: Cardiology Authors: Sarah H. Cross, Neal W. Dickert, Alanna A. Morris, Jabeen Taj, Modele O. Ogunniyi, Dio Kavalieratos Tags: Brief Report Source Type: research
Pitfalls and Opportunities for the Growing Role of AI in Heart Failure
With expanding datasets, more sophisticated algorithms, and increasing computational power, artificial intelligence (AI) has sparked interest in early diagnosis of heart failure (HF), predicting response to therapy, and clinical outcomes. AI algorithms have already been combined with wearable or implanted sensors for remote monitoring to augment HF care. Despite these advancements, the evolving landscape of AI in assessing cardiac function and HF encounters a myriad of challenges and opportunities. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 11, 2024 Category: Cardiology Authors: Jagpreet S. Grewal, Partho P. Sengupta Tags: Perspectives Source Type: research
Capturing the Evolving Landscape of Primary Graft Dysfunction After Heart Transplantation: Will Achilles Ever Overtake the Tortoise?
In Zeno's paradox of Achilles and the tortoise, as described by Aristotle, Achilles races against the tortoise but gives the tortoise a head start. Although Achilles reaches each point where the tortoise has been, the tortoise moves forward, creating new points for Achilles to reach. This process repeats endlessly, indicating that Achilles will never catch up to the tortoise. Conventional outcomes research, using traditional analytical methods, faces analogous challenges in predicting risks in clinical medicine. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 6, 2024 Category: Cardiology Authors: MELANA YUZEFPOLSKAYA, PAOLO C. COLOMBO Tags: Editorial Comment Source Type: research
Capturing the evolving landscape of primary graft dysfunction after heart transplantation. Will Achilles ever overtake the tortoise?
In Zeno's paradox of Achilles and the tortoise, as described by Aristotle, Achilles races against the tortoise but gives the tortoise a head start. Although Achilles reaches each point where the tortoise has been, the tortoise moves forward, creating new points for Achilles to reach. This process repeats endlessly, indicating that Achilles will never catch up to the tortoise. Conventional outcomes research, using traditional analytical methods, faces analogous challenges in predicting risks in clinical medicine. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 6, 2024 Category: Cardiology Authors: Melana Yuzefpolskaya, Paolo C. Colombo Tags: Editorial Comment Source Type: research
Synergy, not Silos: The Intersection of Medical and Surgical Training in Advanced Heart Failure
Multidisciplinary care is a central tenant that impacts every patient with heart failure (HF) who may benefit from advanced therapies. Advanced heart failure and transplant cardiology (AHFTC) specialists and cardiac surgeons come together to evaluate and care for these patients holistically based on the current evidence, yet cross-training between the two specialties often feels sparse and informal. As we have applied to AHFTC and thoracic transplantation/mechanical circulatory support (MCS) fellowships, we have noted a paucity of structured training between fields and have desired more information about the ecosystem of a...
Source: Journal of Cardiac Failure - March 6, 2024 Category: Cardiology Authors: Jenna Skowronski, Alexander G Hajduczok, Laura DiChiacchio Source Type: research
Poor Medication Access as a Driver of Excess Heart-Failure Readmissions Among Patients Living in Economically Deprived Neighborhoods
This study explored patients ’ perspectives on medication access by individuals living in socioeconomically deprived neighborhoods who had experienced HF readmission. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 5, 2024 Category: Cardiology Authors: APOORVA GANGAVELLI, ZIHAO LIU, JEFFREY WANG, ALEXIS OKOH, REBECCA S. STEINBERG, KRISHAN PATEL, SHIVANI A. PATEL, NEAL W. DICKERT, ALANNA A. MORRIS Tags: Brief Report Source Type: research
Poor Medication Access as a Driver of Excess Heart Failure Readmissions Among Patients Living in Economically Deprived Neighborhoods
This study explored patient perspectives on medication access among individuals living in socioeconomically deprived neighborhoods who had experienced HF readmission. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 5, 2024 Category: Cardiology Authors: Apoorva Gangavelli, Zihao Liu, Jeffrey Wang, Alexis Okoh, Rebecca S. Steinberg, Krishan Patel, Shivani A. Patel, Neal W. Dickert, Alanna A. Morris Tags: Brief Report Source Type: research
Temporal outcomes of patients diagnosed with transthyretin cardiac amyloidosis
Transthyretin cardiac amyloidosis (ATTR-CA) is increasingly recognized. Clinical outcomes have evolved over time amidst changes in the diagnostic pathway and advances in therapeutics. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 5, 2024 Category: Cardiology Authors: Nicholas Chan, Sergio Teruya, Alfonsina Mirabal, Ariel Y. Weinsaft, Jeffeny De Los Santos, Samantha Guadalupe, Massiel Jimenez, Carlos Rodriguez, Stephen Helmke, Margaret Cuomo, Dia Smiley, Mathew S. Maurer Source Type: research
Cardiogenic Shock Intravascular Cooling Trial (CHILL-SHOCK)
This study aims to examine the safety of TTC in patients presenting with CS. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 5, 2024 Category: Cardiology Authors: Nikhil Gupta, Rohan J Kalathiya, Nikhil Singh, Nadeem Bandealy, Maryam Neyestanak, Stephanie Besser, Cynthia Arevalo, Janet Friant, John EA Blair, Sandeep Nathan, Atman P Shah, Jonathan Paul Tags: Brief Report Source Type: research
Unmasking HFpEF with Artificial Intelligence: A Disruptive Opportunity for Disease Detection
Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent clinical syndrome that accounts for the majority of heart failure cases around the world. The prevalence of HFpEF has previously been reported to be between 1-5.5% of the general population1. However, this may be underestimated, given that diagnosis remains challenging, owing to a multitude of different etiologies and presentations that can be attributed to HFpEF2. With newly available therapies, making an earlier diagnosis of HFpEF has the potential to significantly change the trajectory of a patient's disease course. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 5, 2024 Category: Cardiology Authors: Amogh Karnik, Madeline Jankowski, Akhil Narang Tags: JCF Ignite! Source Type: research
Leveraging the Full Potential of Wearable Devices in Cardiomyopathies
Over a third of US adults own a wearable device, such as a smartwatch or fitness tracker, and access to these devices continues to rise.1 The potential health value of wearables is due to their broad user base that includes healthy individuals without other healthcare contact, but also the direct access to high-quality multimodal sensors, such as heart rate, exercise, sleep, and more recently electrocardiograms (ECGs) and oxygen saturation right on people's wrists. Despite the broad promise of these devices, there are few examples of successful health applications. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - March 5, 2024 Category: Cardiology Authors: Evangelos K. Oikonomou, Rohan Khera Tags: JCF Ignite! Source Type: research
